Frontiers in Antibody–Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy [PDF]
PharmaceuticalsAntibody–drug conjugates (ADCs) represent a transformative class of targeted therapies designed to deliver potent cytotoxic agents specifically to tumor cells, minimizing systemic toxicity. This review provides a comprehensive overview of ADCs, detailing
Xinghan Li +6 more
doaj +2 more sources
Generation of binder-format-payload conjugate-matrices by antibody chain-exchange [PDF]
Nature CommunicationsThe generation of antibody-drug conjugates with optimal functionality depends on many parameters. These include binder epitope, antibody format, linker composition, conjugation site(s), drug-to-antibody ratio, and conjugation method.
Vedran Vasic +13 more
doaj +2 more sources
EXTH-07. TUMOR-HOMING INDUCED NEURAL STEM CELLS SECRETING A CYTOTOXIC PAYLOAD AS AN ADJUVANT TREATMENT FOR NON-SMALL CELL LUNG CANCER BRAIN METASTASES [PDF]
Neuro-Oncology, 2020 Shawn Hingtgen +2 more
exaly +1 more source
Antibody–Drug Conjugates—A Tutorial Review
Molecules, 2021 Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small ...
Stephanie Baah +2 more
doaj +1 more source
Targeting cancer with antibody-drug conjugates: Promises and challenges
mAbs, 2021 Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S.
Alexis Q. Dean +3 more
doaj +1 more source
Introduction to Antibody-Drug Conjugates
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker.
Mark C. Pettinato
doaj +1 more source
Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates [PDF]
, 2021 Protease-activated prodrugs leverage the increased activity of proteases in the tumor microenvironment and the tight regulation in healthy tissues to provide selective activation of cytotoxins in the tumor while minimizing toxicity to normal tissues. One
Alex Pokora (1881115) +11 more
core +1 more source
Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment [PDF]
, 2021 Although chimeric antigen receptor (CAR) T cells have shown impressive clinical success against haematological malignancies such as B cell lymphoma and acute lymphoblastic leukaemia, their efficacy against non-haematological solid malignancies has been ...
Daniel Fowler +9 more
core +1 more source
Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads [PDF]
ACS Medicinal Chemistry Letters, 2016 The tubulysin class of natural products has attracted much attention from the medicinal chemistry community due to its potent cytotoxicity against a wide range of human cancer cell lines, including significant activity in multidrug-resistant carcinoma models. As a result of their potency, the tubulysins have become an important tool for use in targeted
Carolyn A, Leverett +15 more
openaire +2 more sources
A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types [PDF]
, 2022 To improve tumor selectivity of cytotoxic agents, we designed VIP236, a small molecule–drug conjugate consisting of an αVβ3 integrin binder linked to a modified camptothecin payload (VIP126), which is released by the enzyme neutrophil ...
Ahmed Hamdy +10 more
core +1 more source